Skip to main content

FDA Approvals

FDA OKs Lazertinib With Amivantamab-vmiw for NSCLC

Directory of FDA Approvals, August Through December 2023

Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma

Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma

Ogsiveo First Treatment FDA Approved for Desmoid Tumors

FDA Approvals, Gastroenterology

Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma

Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation

FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma

Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer

Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form

Page 2 of 53
Results 11 - 20 of 522